Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Inhibikase Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
Prev close 2.29 · gapped above the open, then crossed back over prior close. High/low 2.37 at 9:30 am ET, 2.27 at 2:45 pm ET.
106 institutional managers report a position in Inhibikase Therapeutics, Inc. worth $239.2M between them, filed on form 13F for the quarter ending 2026-06-30. 15 of them hold 80% of it, the largest being Sands Capital Ventures, LLC at 11.05%.
81 more managers in the register
15 managers hold 80% of the $239.2M institutional base. The other 91 hold the rest.
Positions as filed with the SEC for the quarter ended Jun 30. A 13F is due 45 days after the quarter closes, so this register is 78 days old and does not move with the price above it.
via ADAR1 Capital Management, LLC, Commodore Capital LP, Blackstone Group L.P. +3 more · 6.27% of IKT, 10.69% of LONA
via Trails Edge Capital Partners, LP, ADAR1 Capital Management, LLC, Commodore Capital LP +1 more · 7.68% of IKT, 6.72% of RACC
via Soleus Capital Management, L.P., Sands Capital Ventures, LLC · 9.23% of IKT, 9.12% of BBNX
via Commodore Capital LP, ADAR1 Capital Management, LLC, Kalehua Capital Management LLC +2 more · 4.58% of IKT, 7.71% of IFRX
via Trails Edge Capital Partners, LP, Commodore Capital LP, Spruce Street Capital LP +2 more · 7.68% of IKT, 5.12% of LBRX
via Siren, L.L.C., Commodore Capital LP, Saturn V Capital Management LLC +1 more · 4.96% of IKT, 5.12% of ZURA
Managers holding a meaningful stake in IKT also hold this much of the other company’s institutional base. Managers who hold most of the companies we cover are excluded, because their overlap says nothing about this one in particular. This is how the two are held, not evidence that one moves the other.
IKT (Inhibikase Therapeutics, Inc.) has 0 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.